An interventional study of group cognitive stimulation therapy and usual care in Cognitive Therapy, sponsored by National Yang Ming Chiao Tung University. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-07.
Sponsored by National Yang Ming Chiao Tung University · Not applicable, Interventional, and Treatment
Background: Cognitive dysfunction is the core defect of schizophrenia, which seriously affects the emotional, social functions and quality of life in people with schizophrenia.
Objective: The purpose of this study is to explore the efficacy of group cognitive stimulation therapy in cognitive function, depressive symptoms, social function, and quality of life in people with Schizophrenia.
Research method:This study used a single-blind randomized controlled trial design. Participants's Montreal Cognitive Assessment Scale (MoCA) score between 10-25 points are include. Chronic rehabilitation wards were randomly assigned to the experimental group and the conventional treatment group using blocking. The experimental group (EG) (n = 45) is receive 7 weeks, twice a week, 60 minutes each time of group cognitive stimulation therapy(GCST), the control group (CG) (n = 45) maintain usual care.
Expected results: GCST can improve cognitive function, depressive symptoms, social function and quality of life in people with schizophrenia.
Background: Cognitive dysfunction is the core defect of schizophrenia, which seriously affects the emotional and social functions of patients. Group cognitive stimulation therapy has been supported by research abroad to improve cognition and mood. Domestically, this group of people with schizophrenia will also face the above symptoms. Therefore, non-pharmacological therapy is among mental health personnel It is worth paying attention to and developing in the process of providing medical services.
Objective: The purpose of this study explores the efficacy of group cognitive stimulation therapy in cognitive function, depressive symptoms, social function and quality of life in people with Schizophrenia.
Research method: This study used a single-blind randomized controlled trial design to reduce it to people with schizophrenia.This study used a single-blind randomized controlled trial design. Participants's Montreal Cognitive Assessment Scale (MoCA) score between 10-25 points are include. Chronic rehabilitation wards were randomly assigned to the EG and the CG using blocking. The EG receive 7 weeks, twice a week, 60 minutes each time of GCST, the CG maintain usual care. Both groups use the Montreal Cognitive Assessment Scale (MoCA), the Taiwanese Version of Frontal Assessment Battery (TFAB), the Beck Depression Inventory II (Beck Depression Inventory II, BDI-II), and Social Function Scales-Taiwanese version(SFST) and WHOQOL-BREF is use as an evaluation tool to measure the results at the baseline, T1 (7th weeks) and T2 (20th weeks). The research results were filed and statistically analyzed with IBM SPSS 20.0 software package. Descriptive statistics were used for general demographic variables and primary , secondary outcome: mean, SD, range, percentage. The difference between the two groups of benchmark values was analyzed with t-test or χ2, independent-t test, pair-t, and GEE.
Expected results: GCST can improve cognitive function, depressive symptoms, social function and quality of life in people with schizophrenia.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's planned enrollment of 90 is above the median of 70 across 2,872 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →National Yang Ming Chiao Tung University is the lead sponsor of 201 studies on the registry; 58 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The experimental group will receive a total of 14 sessions, twice a week group cognitive stimulation therapy for 7 weeks.
Other: group cognitive stimulation therapy · Other: usual care
The control group maintains the usual care.
The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
Also known as: GCST
The control group maintains the unit routine treatment.
Montreal Cognitive Assessment, MoCA
Cognitive function test
Time frame: baseline
Taiwanese Version of Frontal Assessment Battery, TFAB
Cognitive function test
Time frame: baseline
Wechsler Memory Scale-Third Edition, WMS-III
Cognitive function test
Time frame: baseline
Beck Depression Inventory II, BDI-II
Depressive symptoms test
Time frame: baseline
Social Function Scales-Taiwanese version, SFST
Social Function test
Time frame: baseline
WHOQOL-BREF
quality of life test
Time frame: baseline
Montreal Cognitive Assessment, MoCA
Cognitive function test
Time frame: 7th weeks
Taiwanese Version of Frontal Assessment Battery, TFAB
Cognitive function test
Time frame: 7th weeks
Wechsler Memory Scale-Third Edition, WMS-III
Cognitive function test
Time frame: 7th weeks
Beck Depression Inventory II, BDI-II
Depressive symptoms test
Time frame: 7th weeks
Social Function Scales-Taiwanese version, SFST
Social Function test
Time frame: 7th weeks
WHOQOL-BREF
quality of life test
Time frame: 7th weeks
Montreal Cognitive Assessment, MoCA
Cognitive function test
Time frame: 20th week
Taiwanese Version of Frontal Assessment Battery, TFAB
Cognitive function test
Time frame: 20th week
Wechsler Memory Scale-Third Edition, WMS-III
Wechsler Memory Scale-Third Edition, WMS-III
Time frame: 20th week
Beck Depression Inventory II, BDI-II
Depressive symptoms test
Time frame: 20th week
Social Function Scales-Taiwanese version, SFST
Social Function test
Time frame: 20th week
WHOQOL-BREF
quality of life test
Time frame: 20th week
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Yang Ming Chiao Tung University